Inflazome’s Somalix Demonstrates Positive Safety, Tolerability and Pharmacodynamic Profile in its Phase I Study

Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces the successful completion of a Phase I study of its investigational drug, Somalix. Somalix is a small molecule, peripherally-restricted inhibitor of the NLRP3 inflammasome. The Phase I data showed excellent safety and tolerability while pharmacokinetics showed linear increase with dose which could be correlated with pharmacodynamic response. The results further validate Inflazome’s technology platform and support the progression of Somalix into Phase II clinical trials in the second quarter this year.

Inflazome IP Portfolio Strengthened with Patents Granted in US and Europe

Dublin (IE), Cambridge (UK), Brisbane (AU) | 13 January 2020: Inflazome, the pioneering inflammasome biotech company developing multiple small molecule drugs that block harmful inflammation, today announces that the United States Patent and Trademark Office (USPTO) and the European Patent Office (EPO) will grant the patent application WO 2016/131098 as US 10,538,487 on 21 January 2020 and EP 3,259,253 on 15 January 2020.

Inflazome’s CEO admitted as Honorary Fellow to the Royal Society of Chemistry

Dublin (IE), Cambridge (UK), Brisbane (AU) | 18 December 2019: Inflazome, the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, is delighted to announce that Chief Executive Officer, Professor Matt Cooper, has been admitted as an Honorary Fellow to the prestigious Royal Society of Chemistry. The Society was founded in 1841, when 77 scientists, including doctors, academics, manufacturers and entrepreneurs came together with a common mission to leverage academic excellence to advance the chemical sciences.

Inflazome Co-founder and CEO Matt Cooper Named Cross-Field Highly Cited Researcher by Clarivate Analytics

Dublin (IE), Cambridge (UK), Brisbane (AU) | 25 November 2019: Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple small molecule drugs that stop harmful inflammation, is pleased to announce that the Company’s Co-founder and Chief Executive Officer, Matt Cooper, has been named a cross-field highly cited researcher by Clarivate Analytics.

Inflazome Gains Highly Commended Recognition for its Series B Fundraise at the 2019 European Lifestars Awards™

Dublin (IE), Cambridge (UK), Brisbane (AU) | 22 November 2019: Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, is pleased to announce that it has been recognised with a highly commended accolade within the Series B Finance Raise of the Year award at the 2019 Lifestars Awards.™

Inflazome Progresses Two Drugs Into Clinical Trials

Dublin (IE), Cambridge (UK), Brisbane (AU) | 07 November 2019: Inflazome (inflazome.com), the pioneering inflammasome biotech company developing multiple drugs that stop harmful inflammation, today announces that healthy volunteers have been successfully dosed in the company’s Phase I clinical trials of Inzomelid and Somalix, two small molecule inhibitors of the NLRP3 inflammasome. These trials represent an important milestone for Inflazome and confirm its leadership in the inflammasome space.

Inflazome Receives Funding from the Michael J. Fox Foundation for Parkinson's Research

Dublin (IE), Cambridge (UK) | 25th March, 2019: Inflazome (inflazome.com), the pioneering biotech company developing several small molecule drugs that inhibit harmful inflammation, today announces it has been awarded funding in excess of US$1 million by The Michael J. Fox Foundation for Parkinson’s Research (MJFF). The grant will fund the development of a NLRP3-specific Positron Emission Tomography (PET) tracer to allow non-invasive imaging of inflammasome-driven inflammation in the brain.

Inflazome's CSO Ranked #1 Most Cited Irish Scientist by New Citation Database

Dublin (IE), 11th September 2019: Inflazome (inflazome.com), the pioneering, clinical stage, inflammasome biotech company developing multiple small molecule drugs that inhibit harmful inflammation, is pleased to announce that our CSO, Prof. Luke O'Neill has been listed as one world’s most cited scientists by a new citation metrics database. The database systematically and objectively ranks 100,000 of the globe’s most cited scientists based on their research output.

Prof. Marco Colonna M.D Joins Scientific Advisory Board

Dublin (IE), Cambridge (UK) | 18th February 2019: Inflazome (inflazome.com), the pioneering inflammasome company, announces the appointment of distinguished scientist, Prof. Marco Colonna M.D. to its Scientific Advisory Board. Prof. Colonna has deep expertise and extensive experience in innate immunity. His team is responsible for the innovative discovery of Triggering Receptors Expressed on Myeloid cells (TREM), important regulators of the innate immune response. Prof. Colonna is currently investigating TREM’s link to Alzheimer’s Disease at the Washington University School of Medicine in St. Louis, MO, where he has been a Professor of Pathology and Immunology since 2001.

Inflazome's Drug Discovery and Development Efforts Highlighted in Nature Biotechnology News Article

Dublin (IE), Cambridge (UK) | 23 January 2019: Inflazome’s drug discovery and development efforts highlighted in Nature Biotechnology News Article.

Appointment of Dr Thomas Jung as Chief Medical Officer

Dublin, Ireland and Cambridge, UK | 29th November 2018: Inflazome (inflazome.com), the pioneering inflammasome company, announces the appointment of Dr Thomas Jung M.D., Ph.D., as its Chief Medical Officer.

Inflazome Completes €40m ($46m) Series B Financing to Develop NLRP3 Inflammasome Inhibitorsto Clinical Proof-of-Concept

Dublin, Ireland and Cambridge, U.K. | 19 November 2018:Inflazome, a pioneering inflammasome company developing small molecule drugs that block harmful inflammation, today announces the successful completion of a Series B financing round of €40 million ($46 million). The financing round was led by Forbion, with Longitude Capital and founding investors, Novartis Venture Fund and Fountain Healthcare Partners, also participating.

Inflazome's CSO Awarded the 2018 Seymour & Vivian Milstein Award for Excellence in Interferon and Cytokine Research

Dublin (IE) | 08 May 2018: The International Cytokine and Interferon Society (ICIS) announced today that the Seymour and Vivian Milstein Award has been bestowed on two world leaders in deciphering the role of innate immunity in the host immune response. Inflazome's Chief Scientific Officer Luke O’Neill, PhD and Thirumala-Devi Kanneganti, PhD will share the 2018 Seymour and Vivian Milstein Award for Excellence in Cytokine and Interferon Research (“The Milstein Award”).

Inflazome Presents at Trinity Healthcare Entrepreneurship Forum

Dublin (IE) | 07 March 2018: Inflazome's VP Business Development Dr Jeremy Skillington joins a panel discussion at the second Trinity Healthcare Entrepreneurship Forum of the Trinity Biomedical Sciences Institute (TBSI).

Reported in The University Times: From Surgery to Startups, at TSBI

Inflazome Responds to the Cantos Trial in the New England Journal of Medicine

Dublin (IE), Cambridge (UK) | 11 January 2018: Inflazome's CSO Dr Luke O'Neill and CEO Dr Matt Cooper publish a letter to the editor in The New England Journal of Medicine (NEJM) today, commenting on the Canakinumab Antiinflammatory Thrombosis Outcome Study (CANTOS) by Ridker et al. that found reduced inflammation was associated with reduced cardiovascular risk.

Inflazome Appoints Renowned Harvard Cardiologist to its Scientific Board

Dublin (IE), Cambridge (UK) | 04 January 2018: Inflazome Ltd, a biotech company developing small molecule drugs that stop harmful inflammation, today announces the appointment of Prof. Paul Ridker to Inflazome’s Scientific Advisory Board. Prof. Ridker is a leading scientific expert in cardiovascular disease and is renowned for his work on inflammation and its role in heart disease. Medical researcher and the Eugene Braunwald Professor of Medicine at Harvard University, Prof. Ridker also directs the Center for Cardiovascular Disease Prevention at the Brigham and Women’s Hospital in Boston, Massachusetts.

Inflazome Appoints Renowned Scientific, Industry & Clinical Experts

Dublin (IE), Cambridge (UK) | 28 November 2017:Inflazome Ltd, the biotech company developing small molecule drugs that stop harmful inflammation, today announces the appointment of three leading scientific, industry & clinical experts to its Scientific Advisory Board and Board of Directors.

Inflazome's CSO Wins Trinity Provost Innovation Award

Dublin, Ireland – 28 November 2017 - Researchers at Trinity College Dublin were acknowledged for their innovative research and entrepreneurship at the Trinity Innovation Awards 2017 special awards ceremony last night [November 27th, 2017].

Inflazome's Chief Scientific Officer Ranked in the Top 1% of the World's Immunologists

Dublin, Ireland – 24 November, 2017 - Inflazome’s Co-Founder and Chief Scientific Officer, Professor Luke O’Neill, has been ranked in the top 1% of highly cited immunology researchers by Clarivate Analytics, a global leader in insights and analytics. Prof. O’Neill’s academic group at Trinity College Dublin works on the molecular basis of innate immunity and inflammation.

Inflazome Establishes Cambridge Office

February 6, 2017 – Cambridge, UK - Inflazome, Ltd., a biotech company developing small molecule drugs that stop inflammation driven by our innate immune system, today opened a new office in Cambridge, UK to accommodate employees in the centre of theUK’s pharmaceutical industry.

Inflazome Expands Management Team

November 01, 2016 – Dublin, Ireland and Cambridge, UK – Inflazome, Ltd., a biotech company developing small molecule drugs that stop inflammation driven by our innate immune system, today announced the appointment of two industry leaders with extensive drug discovery and development expertise to its Management Team.

Inflazome Closes Series A Financing

September 12, 2016 -- Dublin, Ireland -- Inflazome (inflazome.com) has successfully closed a Series A financing round for up to USD$17 million / €15 million. Two leading life sciences venture capital firms, Novartis Venture Funds and Fountain Healthcare Partners, co-led the financing.

The New Yorker Writes About Inflammation

Medical journalist Jerome Groopman writes an informative article about how medical researchers are finding that inflammation is the root cause of many of our most challenging conditions. Read the full article.

Read the full article

Dr Matt Cooper Interviewed by ABC News Australia

Stephanie Smail from ABC News Australia interviews Dr. Matt Cooper about how new scientific discoveries could be the key to better treatments for Alzheimer's, arthritis and MS. Read the full transcript.

The Irish Times Interviews Prof. Luke O'Neill About New Advances in Blocking Inflammation

The Irish Times interviewed Prof Luke O'Neill about his research in using small molecules to block inflammation. Early mice studies show exceptional promise in blocking multiple sclerosis, and additional tests reveal the molecules could also halt diseases such as rheumatoid arthritis and alzheimer’s. Read the full article here.